Cardiol Therapeutics Shares Drop After Topline Results From Phase 2 Trial in Acute Myocarditis

MT Newswires Live

2025/08/06

Cardiol Therapeutics (CRDL) shares were down 15.9% in recent Wednesday trading after the company said topline results from a phase 2 trial of CardiolRx showed a "notable" improvement in extracellular volume, with "no significant difference" in global longitudinal strain among patients with preserved left ventricular function at baseline.

Extracellular volume and global longitudinal strain, measured after 12 weeks of double-blind therapy, were the two primary endpoints of the study, the company said.

Cardiol said the results of the study provide clinical proof of concept for CardiolRx and support advancing its clinical development and that of CRD-38, another investigational drug, in cardiomyopathies, heart failure, and myocarditis.

CardiolRx was also observed to be safe and well-tolerated, the company added.

Price: 1.14, Change: -0.22, Percent Change: -15.93

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎證券香港 | 輕鬆買賣美股港股A股/美債/ETF/Crypto/期權期貨","description":"老虎證券香港提供多種優惠: 港股&Crypto 0佣0平台費、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","keywords":"老虎證券,老虎證券開戶,老虎證券香港,老虎證券投資,老虎證券美股,老虎證券登錄,證券開戶,證券公司開戶,股票開戶,香港證券公司,香港證券,證券公司,美股投資平台,小額投資理財,投資app,投資平台,股票買賣,買賣股票平台,炒股app,證券app,新手投資","social":{"ogDescription":"老虎證券香港提供多種優惠: 港股&Crypto 0佣0平台費、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2557054933"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2557054933\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2557054933?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-06 23:12","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2557054933","market":"fut","top_or_hot":-1,"title":"Cardiol Therapeutics Shares Drop After Topline Results From Phase 2 Trial in Acute Myocarditis","media":"MT Newswires Live","content":"<html><body><p> Cardiol <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (CRDL) shares were down 15.9% in recent Wednesday trading after the company said topline results from a phase 2 trial of CardiolRx showed a \"notable\" improvement in extracellular volume, with \"no significant difference\" in global longitudinal strain among patients with preserved left ventricular function at baseline.</p><p>Extracellular volume and global longitudinal strain, measured after 12 weeks of double-blind therapy, were the two primary endpoints of the study, the company said.</p><p>Cardiol said the results of the study provide clinical proof of concept for CardiolRx and support advancing its clinical development and that of CRD-38, another investigational drug, in cardiomyopathies, heart failure, and myocarditis.</p><p>CardiolRx was also observed to be safe and well-tolerated, the company added.</p><p>Price: 1.14, Change: -0.22, Percent Change: -15.93</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cardiol Therapeutics Shares Drop After Topline Results From Phase 2 Trial in Acute Myocarditis</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCardiol Therapeutics Shares Drop After Topline Results From Phase 2 Trial in Acute Myocarditis\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time smaller\">2025-08-06 23:12</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p> Cardiol <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (CRDL) shares were down 15.9% in recent Wednesday trading after the company said topline results from a phase 2 trial of CardiolRx showed a \"notable\" improvement in extracellular volume, with \"no significant difference\" in global longitudinal strain among patients with preserved left ventricular function at baseline.</p><p>Extracellular volume and global longitudinal strain, measured after 12 weeks of double-blind therapy, were the two primary endpoints of the study, the company said.</p><p>Cardiol said the results of the study provide clinical proof of concept for CardiolRx and support advancing its clinical development and that of CRD-38, another investigational drug, in cardiomyopathies, heart failure, and myocarditis.</p><p>CardiolRx was also observed to be safe and well-tolerated, the company added.</p><p>Price: 1.14, Change: -0.22, Percent Change: -15.93</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2557054933","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2557054933","pubTimestamp":1754493170,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Cardiol Therapeutics (CRDL) shares were down 15.9% in recent Wednesday trading after the company said topline results from a phase 2 trial of CardiolRx showed a \"notable\" improvement in extracellular ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","LENZ":"Therapeutics","BK4007":"制药","BK4539":"次新股","CRDL":"Cardiol Therapeutics Inc"},"translate_title":"急性心肌炎2期试验取得主要结果后，Cardiol Therapeutics股价下跌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CRDL":0.9,"LENZ":1},"content_text":"Cardiol Therapeutics (CRDL) shares were down 15.9% in recent Wednesday trading after the company said topline results from a phase 2 trial of CardiolRx showed a \"notable\" improvement in extracellular volume, with \"no significant difference\" in global longitudinal strain among patients with preserved left ventricular function at baseline.Extracellular volume and global longitudinal strain, measured after 12 weeks of double-blind therapy, were the two primary endpoints of the study, the company said.Cardiol said the results of the study provide clinical proof of concept for CardiolRx and support advancing its clinical development and that of CRD-38, another investigational drug, in cardiomyopathies, heart failure, and myocarditis.CardiolRx was also observed to be safe and well-tolerated, the company added.Price: 1.14, Change: -0.22, Percent Change: -15.93","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}